CY1110879T1 - ΧΑΡΑΚΤΗΡΙΣΜΟΣ: ΑΝΑΜΙΚΤΟΙ ORL1/μ-ΑΓΩΝΙΣΤΕΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΠΟΝΟΥ - Google Patents

ΧΑΡΑΚΤΗΡΙΣΜΟΣ: ΑΝΑΜΙΚΤΟΙ ORL1/μ-ΑΓΩΝΙΣΤΕΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΠΟΝΟΥ

Info

Publication number
CY1110879T1
CY1110879T1 CY20101100993T CY101100993T CY1110879T1 CY 1110879 T1 CY1110879 T1 CY 1110879T1 CY 20101100993 T CY20101100993 T CY 20101100993T CY 101100993 T CY101100993 T CY 101100993T CY 1110879 T1 CY1110879 T1 CY 1110879T1
Authority
CY
Cyprus
Prior art keywords
orl1
receptor
agonist
pain
anticipators
Prior art date
Application number
CY20101100993T
Other languages
English (en)
Inventor
Klaus Linz
Babette-Yvonne Kögel
Wolfgang Schröder
Thomas Christoph
Vry Jean De
Elmar Friderichs
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1110879T1 publication Critical patent/CY1110879T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση αφορά τη χρησιμοποίηση ενώσεων, οι οποίες παρουσιάζουν μία χημική συγγένεια προς τον υποδοχέα μ-οπιοειδών από τουλάχιστον 100 nΜ (ανθρώπινη τιμή Κi) και μία χημική συγγένεια προς τον ORL1 -υποδοχέα, όπου η αναλογία μεταξύ χημικών συγγενειών ORL1/μ, προσδιορισμένη σαν 1/[Ki(ORL1)/Κi(μ)], βρίσκεται από 0,1 έως 30, για την παρασκευή ενός φαρμάκου για τη θεραπεία πόνου.
CY20101100993T 2006-09-29 2010-11-03 ΧΑΡΑΚΤΗΡΙΣΜΟΣ: ΑΝΑΜΙΚΤΟΙ ORL1/μ-ΑΓΩΝΙΣΤΕΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΠΟΝΟΥ CY1110879T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006046745A DE102006046745A1 (de) 2006-09-29 2006-09-29 Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
EP07818462A EP2081571B1 (de) 2006-09-29 2007-09-26 GEMISCHTE ORL1/µ -AGONISTEN ZUR BEHANDLUNG VON SCHMERZ

Publications (1)

Publication Number Publication Date
CY1110879T1 true CY1110879T1 (el) 2015-06-10

Family

ID=38982475

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100993T CY1110879T1 (el) 2006-09-29 2010-11-03 ΧΑΡΑΚΤΗΡΙΣΜΟΣ: ΑΝΑΜΙΚΤΟΙ ORL1/μ-ΑΓΩΝΙΣΤΕΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΠΟΝΟΥ
CY20121100252T CY1112471T1 (el) 2006-09-29 2012-03-12 Αναμικτοι orl1/μ-αγωνιστες για τη θεραπεια πονου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100252T CY1112471T1 (el) 2006-09-29 2012-03-12 Αναμικτοι orl1/μ-αγωνιστες για τη θεραπεια πονου

Country Status (13)

Country Link
US (3) US20080125475A1 (el)
EP (2) EP2206498B9 (el)
JP (2) JP5203373B2 (el)
AT (2) ATE542532T1 (el)
CA (1) CA2664702C (el)
CY (2) CY1110879T1 (el)
DE (2) DE102006046745A1 (el)
DK (2) DK2206498T3 (el)
ES (2) ES2351528T3 (el)
PL (2) PL2081571T3 (el)
PT (2) PT2206498E (el)
SI (2) SI2206498T1 (el)
WO (1) WO2008040481A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009319A1 (de) * 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
ES2621407T3 (es) 2008-03-27 2017-07-04 Grünenthal GmbH Ciclohexildiaminas sustituidas
AU2009228643B2 (en) 2008-03-27 2013-07-11 Grunenthal Gmbh Spiro(5.5)undecane derivatives
CA2719742C (en) 2008-03-27 2016-11-08 Gruenenthal Gmbh Substituted spirocyclic cyclohexane derivatives
PE20121314A1 (es) 2008-03-27 2012-10-07 Gruenenthal Chemie Derivados de 4-aminociclohexano sustituido
PT2271613E (pt) 2008-03-27 2014-07-16 Gruenenthal Gmbh Hidroximetilciclo-hexilamina
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
DE102009041581B4 (de) 2009-09-15 2011-09-29 Airbus Operations Gmbh Vorrichtung zur Abgrenzung eines Crew-Ruhebereichs und Verfahren zur Inbetriebnahme einer derartigen Vorrichtung
TWI582092B (zh) * 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
MX345068B (es) * 2010-08-04 2017-01-16 Gruenenthal Gmbh Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4', 9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina .
JP5792299B2 (ja) * 2010-08-04 2015-10-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 神経因性疼痛の治療のための６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形
ES2553742T3 (es) * 2010-08-04 2015-12-11 Grünenthal GmbH Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
EP2600846B1 (en) * 2010-08-04 2015-11-25 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
LT2729470T (lt) 2011-07-08 2017-08-25 Grünenthal GmbH Kristalinis (1r,4r)-6`-fluor-n,n-dimetil-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-aminas
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
US8779160B2 (en) 2011-12-12 2014-07-15 Gruenenthal Gmbh Process for the preparation of (1r,4r)-6′-fluoro-(N,N-dimethyl- and N-methyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine
CN106432256B (zh) 2011-12-12 2019-08-09 格吕伦塔尔有限公司 盐酸盐的固体形式
TWI567078B (zh) 2011-12-12 2017-01-21 歌林達有限公司 （１ｒ，４ｒ）－６’－氟－（Ｎ，Ｎ－二甲基）－４－苯基－４’，９’－二氫－３’Ｈ－螺－［環己烷－１，１’－吡喃並－［３，４，b］吲哚］－４－胺及硫酸之固體形式
US20130211351A1 (en) 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
MX353740B (es) * 2012-02-03 2018-01-26 Gruenenthal Gmbh (1r,4r)-6´-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4´,9´-dihidro- 3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indol]-4-amina para el tratamiento de fibromialgia y sindrome de fatiga cronica.
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9358022B2 (en) 2012-05-21 2016-06-07 Noha, Llc Clot removal device and method of using same
WO2015128088A1 (en) 2014-02-27 2015-09-03 Grünenthal GmbH Process for the preparation of 5-fluorotryptophol
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
MX2018010367A (es) 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
NZ508765A (en) * 1998-06-12 2003-10-31 Sod Conseils Rech Applic Beta-carboline derivatives and pharmaceuticals thereof that selectively bind somatostatin receptor subtypes
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
ATE289307T1 (de) * 1998-10-23 2005-03-15 Pfizer 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten
EP1537110B1 (en) * 1999-12-06 2007-01-17 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
ATE302770T1 (de) * 1999-12-06 2005-09-15 Euro Celtique Sa Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
CA2439859A1 (en) * 2001-03-02 2002-09-12 Donna-Donigi Gale N-but-3-enyl norbuprenorphine and its use as analgesic
MY126268A (en) * 2001-11-07 2006-09-29 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
EP1560806B1 (de) * 2002-11-12 2007-01-10 Grünenthal GmbH 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
WO2005033112A2 (en) * 2003-10-02 2005-04-14 Cephalon, Inc. Substituted indole derivatives
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2005314347A (ja) * 2004-04-30 2005-11-10 Japan Tobacco Inc 疼痛抑制剤
DE102004023635A1 (de) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz

Also Published As

Publication number Publication date
ES2377482T3 (es) 2012-03-28
PT2206498E (pt) 2012-02-15
DK2081571T3 (da) 2010-11-08
EP2081571B1 (de) 2010-08-25
ATE542532T1 (de) 2012-02-15
PL2206498T3 (pl) 2012-04-30
DE502007004875D1 (de) 2010-10-07
US20150342929A1 (en) 2015-12-03
CA2664702C (en) 2016-08-09
DK2206498T3 (da) 2012-03-19
DE102006046745A1 (de) 2008-04-03
ATE478667T1 (de) 2010-09-15
SI2081571T1 (sl) 2010-12-31
SI2206498T1 (sl) 2012-03-30
JP2013116907A (ja) 2013-06-13
ES2351528T3 (es) 2011-02-07
US20080125475A1 (en) 2008-05-29
JP5203373B2 (ja) 2013-06-05
US20110015220A1 (en) 2011-01-20
CA2664702A1 (en) 2008-04-10
EP2206498B9 (de) 2012-04-18
EP2206498A1 (de) 2010-07-14
EP2206498B1 (de) 2012-01-25
PT2081571E (pt) 2010-11-29
WO2008040481A1 (de) 2008-04-10
PL2081571T3 (pl) 2011-02-28
JP5698282B2 (ja) 2015-04-08
EP2081571A1 (de) 2009-07-29
JP2010504926A (ja) 2010-02-18
CY1112471T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CY1112471T1 (el) Αναμικτοι orl1/μ-αγωνιστες για τη θεραπεια πονου
Vallejo et al. Pharmacology of opioids in the treatment of chronic pain syndromes
Pascoe Opioid analgesics
Lalley μ-Opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances
White et al. Pharmacological properties of ketamine
Robertson Managing pain in feline patients
KR101195819B1 (ko) 하지 불안 증후군 및 중독 질환을 치료하는데 유용한α-아미노아미드 유도체
Lê et al. Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse
JP2010513569A (ja) アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
Emery et al. Drug-specific differences in the ability of opioids to manage burn pain
JP2015509075A (ja) ノルイボガインの硫酸エステル
WO2008025790A3 (en) Use of opioid formulations in needle-less drug delivery devices
May et al. Morphine has latent deleterious effects on the ventilatory responses to a hypoxic challenge
Seckler et al. Nitrosyl factors play a vital role in the ventilatory depressant effects of fentanyl in unanesthetized rats
Taffe et al. Effects of α-pyrrolidino-phenone cathinone stimulants on locomotor behavior in female rats
NZ590981A (en) Transdermal therapeutic system (TTS) for administration with a wafer
Getsy et al. L-NAC reverses of the adverse effects of fentanyl infusion on ventilation and blood-gas chemistry
Gregoretti et al. Clonidine in perioperative medicine and intensive care unit: more than an anti-hypertensive drug
Sorge et al. The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration
WO2007035879A3 (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
Sanghvi et al. Comparative study of bupivacaine alone and bupivacaine along with buprenorphine in axillary brachial plexus block: a prospective, randomized, single blind study
Lehmann Opioids: overview on action, interaction and toxicity
Park et al. The influence of age and gender on remifentanil EC50 for preventing rocuronium induced withdrawal movements
Ko et al. Pleiotropic effects of kappa opioid receptor-related ligands in non-human primates
Gerak et al. OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects